Anti-VLA-4 monoclonal antibody R1-2

Drug Profile

Anti-VLA-4 monoclonal antibody R1-2

Alternative Names: Anti-alpha-4-integrin monoclonal antibody R1-2; Anti-integrin-alpha-4 monoclonal antibody R1-2

Latest Information Update: 29 Oct 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School; Stanford University
  • Developer Biogen Idec; Harvard Medical School; Stanford University
  • Class Monoclonal antibodies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 10 Aug 2000 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top